Cannabis has a real place in migraine treatment, and it sits in a narrower spot than the dispensary market suggests. The strongest evidence is for treating an active attack. The Cuttler 2020 analysis of Strainprint app data, covering more than 12,000 inhaled-cannabis sessions, found that users reported roughly a 50 percent reduction in headache and migraine severity. The Stith 2020 study reached compatible conclusions from a different dataset. What both share is a focus on the acute attack: cannabis taken when the headache is already present, to bring the severity down. That is where the evidence is strongest and where most migraine patients who use cannabis report the clearest benefit.
Migraine is a mixed pain syndrome, which is why it sits in the Pain cluster rather than standing alone. An attack involves nociceptive components (the vascular and meningeal pain of the headache itself) and, in chronic migraine, nociplastic components (central sensitization that lowers the threshold for the next attack). The mixed mechanism is part of why a single cannabinoid protocol does not fit every migraine patient, and why the acute-versus-preventive distinction matters more here than in most pain conditions.
The risk that the dispensary market never raises is rebound. Medication overuse headache is a documented condition in which frequent use of any acute headache treatment, triptans and NSAIDs and opioids included, increases headache frequency over time rather than reducing it. Cannabis used too often for acute migraine carries the same theoretical risk, and a patient who finds that cannabis aborts attacks can drift into using it most days, which is the exact pattern that drives rebound. This page treats that risk as central rather than as a footnote, because the medical-authority position on migraine has to include the part the product marketing leaves out.
What does the research actually show about cannabis for migraine?
The migraine cannabis evidence is mostly observational, and within that limit it is reasonably consistent. The Cuttler 2020 study in the Journal of Pain analyzed Strainprint app data from 1,300 patients across more than 12,000 cannabis-use sessions for headache and migraine. Self-reported severity dropped by roughly half after inhaled cannabis use. The study also found a concerning signal: headache severity reduction did not change over time, but the doses patients used crept upward, which is the kind of tolerance pattern that precedes medication overuse. The authors flagged this directly.
The Stith 2020 study in Scientific Reports drew on the Releaf App dataset and reached a similar place: most users reported meaningful symptom relief from cannabis used for headache, with the effect concentrated in acute use. Baron 2018 in the Journal of Headache and Pain surveyed a large cannabis-using patient population and found migraine and headache among the most common reasons for use, with many patients reporting substitution away from conventional medications including opioids. Nielsen 2019 added survey data on use patterns across headache disorders.
What the field does not yet have is a strong randomized controlled trial of plant cannabis or edibles for migraine. The Aviram 2017 meta-analysis of cannabis for pain included headache data but noted the same gap: the evidence is built on observational and survey work, not on the placebo-controlled trials that would let a neurologist recommend cannabis with the confidence they bring to triptans or CGRP antagonists. The honest position is that the patient-reported signal is consistent and the controlled evidence is thin, and both halves of that sentence are true at once.
The Lochte 2017 review added useful historical context: cannabis was a documented headache treatment in 19th-century Western medicine before prohibition removed it from the pharmacopoeia, and the modern observational data is in some sense rediscovering a use that was clinically established and then lost. That history does not substitute for trial evidence, but it does mean the contemporary interest is not a novelty.
How does the acute-versus-preventive split change the protocol?
For acute treatment, the goal is to abort or blunt an attack that is already starting, and speed is the constraint. A fast-onset format (nano-emulsion gummy, sublingual tincture, or a beverage) at 5 to 10mg THC taken at the first sign of an attack gives the best chance of catching it before it peaks. A traditional gummy that takes 60 to 90 minutes to take effect is usually too slow for migraine, because the attack has often escalated past the point where a moderate dose can pull it back. Pairing the THC with 5 to 10mg of CBD is reasonable for the anxiety that accompanies a severe attack, with the understanding that the THC is doing the analgesic work.
For preventive use, the pattern that survey respondents describe is a low consistent daily dose (2.5 to 5mg THC, often with equal or higher CBD), taken in the evening. The logic, to the extent the endocannabinoid deficiency hypothesis holds, is that a steady baseline cannabinoid level raises the attack threshold rather than treating any single headache. The evidence for prevention is weaker than for acute use, and a patient pursuing preventive cannabis should track attack frequency carefully and involve a headache specialist, because the conventional preventive options (CGRP antagonists in particular) have strong trial evidence that cannabis cannot match.
The two patterns do not combine freely, and this is the heart of the rebound problem. A patient who uses a low preventive dose every evening and then adds acute dosing during attacks can easily reach daily use, which is the threshold where medication overuse headache becomes a real concern. The cleaner approach is to pick one strategy at a time: either acute treatment capped at two days per week, or a preventive trial with acute attacks handled by a non-cannabis abortive, evaluated over two to three months with a specialist.
What is medication overuse headache, and how does cannabis fit?
Medication overuse headache is one of the most common causes of chronic daily headache, and it is the migraine complication most relevant to cannabis. The mechanism, described in the Diener 2016 review in Lancet Neurology, is that frequent use of acute headache treatments alters central pain processing in a way that increases baseline headache frequency. A patient who starts with episodic migraine and treats each attack aggressively can transition to chronic daily headache, at which point the treatment that was helping individual attacks has become a driver of the overall condition.
The diagnostic threshold for most acute treatments is use on 10 or more days per month for triptans and combination analgesics, or 15 or more days per month for simple analgesics. Cannabis is not formally included in the medication overuse headache criteria, because the trial work to establish its threshold has not been done. The Cuttler 2020 tolerance signal (rising doses over time without rising benefit) is the kind of pattern that precedes overuse, which is why the conservative position is to treat cannabis like other acute treatments and cap use at two to three days per week.
For a patient already in a medication overuse pattern, the treatment is withdrawal of the overused acute medication under specialist guidance, often with a preventive medication started during the withdrawal window. Cannabis can complicate this picture in both directions: it can serve as a bridge that makes withdrawal from triptans or opioids more tolerable, or it can become the overused agent itself. Either way, the patient managing medication overuse headache needs a headache specialist directing the process, not a self-managed cannabis protocol.
How does cannabis interact with migraine medications?
Three interaction categories matter for the migraine population. The serotonin concern comes first. Triptans (sumatriptan, rizatriptan, and the rest of the class) are serotonergic agents, and the combination with THC has rare reports of mood alteration and, very rarely, serotonin-related symptoms. The interaction is uncommon and most patients tolerate the combination, but the migraine population uses triptans heavily, so it is worth naming. Patients who notice unexpected anxiety or unusual symptoms after combining a triptan with cannabis should separate the two and consult the prescriber.
The CBD enzyme-inhibition concern comes second. CBD slows the cytochrome P450 enzymes that metabolize several preventive migraine medications, including some beta-blockers (propranolol, metoprolol) and several antidepressants used for prevention (amitriptyline, venlafaxine). Slowed metabolism raises blood levels of those medications. The effect is most pronounced at higher CBD doses, and the protocols on this page stay modest, but a patient on a preventive regimen should still involve the prescriber before adding daily cannabis.
The third concern is the newer migraine drug classes. CGRP antagonists (the -gepant acute drugs and the monoclonal antibody preventives) and ditans (lasmiditan) are recent enough that the cannabis interaction data is sparse. Lasmiditan in particular causes significant sedation on its own, and combining it with THC compounds that sedation meaningfully. A patient on lasmiditan should treat the combined sedation as a real driving and functioning hazard, not a minor additive effect.